Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Aug;30(4):1641-5.
doi: 10.1007/s10637-011-9717-2. Epub 2011 Jul 13.

Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil

Affiliations
Clinical Trial

Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil

Valerie Florin et al. Invest New Drugs. 2012 Aug.

Abstract

Background: Despite multiple available options, the treatment of cutaneous melanoma metastases is often unsuccessful. Based on the hypothesis that imiquimod and 5-fluorouracil have synergistic antitumor properties, we used this topical combination to treat several patients.

Aim: Our objective was to investigate the treatment combination in a small cohort of patients with surgically non-resectable melanoma metastases.

Methods: The lesions of 5 patients with multiple cutaneous metastases were treated topically, 5 days per week, with 5-fluorouracil in the morning and imiquimod at night.

Results: 45 lesions were treated. A clinical response was seen in 44 lesions, with a complete response in 19 lesions and a partial response in 25. Stable disease was confirmed in the 1 remaining lesion. No patients developed new lesions during treatment. However, one patient had a recurrence 6 months after treatment discontinuation, followed by a partial response when rechallenged.

Conclusions: The imiquimod and 5-fluorouracil combination is effective. That patients did not develop new, distant lesions suggests the achievement of locoregional control, probably by the induction of antitumor immune response.

PubMed Disclaimer

References

    1. J Am Acad Dermatol. 2000 Sep;43(3):555-6 - PubMed
    1. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
    1. J Cutan Pathol. 2009 Aug;36(8):878-81 - PubMed
    1. Clin Exp Dermatol. 2008 Jan;33(1):74-6 - PubMed
    1. Br J Dermatol. 2007 Feb;156(2):337-45 - PubMed

Publication types

MeSH terms

LinkOut - more resources